1. Individual omega-9 monounsaturated fatty acids and mortality—The Ludwigshafen Risk and Cardiovascular Health Study 
Graciela E. Delgado, MSc, Bernhard K. Krämer, MD, Stefan Lorkowski, PhD, Winfried März, MD, Clemens von Schacky, MD, Marcus E. Kleber, PhD 
Journal of Clinical Lipidology 
Volume 11, Issue 1, Pages e5 (January 2017)
DOI: /j.jacl
Copyright © 2016 National Lipid Association Terms and Conditions

2. Figure 1
Metabolism of omega-9 fatty acids in humans. The three omega-9 fatty acids analyzed in this study are red-rimmed.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

3. Figure 2
Association of omega-9 FA with mortality. Risk of all-cause mortality per 1-SD increase in OA, GA, and NA in the whole cohort (A), men (B), and women (C). Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes mellitus, smoking, and lipid-lowering therapy; model 3: additionally adjusted for eGFR. BMI, body mass index; GA, gondoic acid; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; NA, nervonic acid; OA, oleic acid; TG, triglycerides.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

4. Figure 3
Relationship between omega-9 MUFA and all-cause mortality. OA (A), GA (B), and NA (C) were modeled as restricted cubic spline in Cox regression analysis adjusted for age, gender, BMI, LDL-C, HDL-C, logTG, hypertension, diabetes mellitus, smoking and lipid-lowering therapy. Their concentration was plotted against the respective log relative hazard with 95% confidence intervals. GA, gondoic acid; NA, nervonic acid; OA, oleic acid.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

5. Figure 4
Correlation analysis of omega-9 MUFA with LA, ARA, EPA, DHA and SFA. A darker coloration indicates a stronger correlation. Correlations not significant at α < 0.01 have white background. ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; SFA, total saturated fatty acids.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

6. Figure 5
Adjusted survival curves for cardiovascular mortality. Quartiles of nervonic acid were balanced for age, gender, eGFR, smoking, diabetes mellitus, EPA, ARA, and LA by inverse variance weighting. The inset shows the same data on a truncated y-axis. The P value of the robust score test was 5.78e−14. ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

7. Supplementary Figure 1
Distribution of omega-9 MUFA in LURIC. Box plots showing the distribution of OA (A), GA (B), and NA (C) in LURIC stratified by gender. The boxes represent the interquartile ranges (IQR), median values are shown as black lines. Whiskers extend to the data point closest to a distance 1.5 times the IQR away from the median.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

8. Supplementary Figure 2
Association of omega-9 MUFA with cardiovascular mortality. Risk of cardiovascular mortality per 1-SD increase of OA, GA, and NA in men (A), women (B), and combined (C). Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, and lipid-lowering therapy; model 3: additionally adjusted for eGFR. BMI, body mass index; GA, gondoic acid; HDL-C, HDL cholesterol; LA, Linoleic acid; LDL-C, LDL cholesterol; NA, nervonic acid; OA, oleic acid; TG, triglycerides.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

9. Supplementary Figure 3
Association of omega-9 MUFA with cardiovascular mortality in participants with coronary artery disease at baseline. Risk of cardiovascular mortality per 1-SD increase in OA, GA and NA. Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking and lipid-lowering therapy; model 3: additionally adjusted for eGFR. BMI, body mass index; GA, gondoic acid; HDL-C, HDL cholesterol; LA, linoleic acid; LDL-C, LDL cholesterol; NA, nervonic acid; OA, oleic acid; TG, triglycerides.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

10. Supplementary Figure 4
Association of omega-9 MUFA with cardiovascular mortality in participants with chronic kidney disease at baseline. Risk of cardiovascular mortality per 1-SD increase in OA, GA, and NA. Model 1, adjusted for age and gender; model 2, additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, and lipid-lowering therapy; model 3, additionally adjusted for eGFR. BMI, body mass index; GA, gondoic acid; HDL-C, HDL cholesterol; LA, linoleic acid; LDL-C, LDL cholesterol; NA, nervonic acid; OA, oleic acid; TG, triglycerides.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions

11. Supplementary Figure 5
Association of omega-9 MUFA with cardiovascular mortality in study participants without CAD and without CKD at baseline. Risk of cardiovascular mortality per 1-SD increase in OA, GA, and NA. Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, and lipid-lowering therapy; model 3: additionally adjusted for eGFR. BMI, body mass index; GA, gondoic acid; HDL-C, HDL cholesterol; LA, linoleic acid; LDL-C, LDL cholesterol; NA, nervonic acid; OA, oleic acid; TG, triglycerides.
Journal of Clinical Lipidology  , e5DOI: ( /j.jacl )
Copyright © 2016 National Lipid Association Terms and Conditions